Wu Tian, Zeng Zheng, Yu Yanyan
Department of Infectious Diseases, Peking University First Hospital, Beijing 100034, China.
Microorganisms. 2024 May 17;12(5):1020. doi: 10.3390/microorganisms12051020.
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver condition worldwide. Numerous studies conducted recently have demonstrated a connection between the dysbiosis of the development of NAFLD and gut microbiota. Rebuilding a healthy gut ecology has been proposed as a strategy involving the use of probiotics. The purpose of this work is to investigate and compare the function of probiotics () and VSL#3 in NAFLD mice. Rodent NAFLD was modeled using a methionine choline-deficient diet (MCD) with/without oral probiotic delivery. Subsequently, qPCR, histological staining, and liver function tests were conducted. Mass spectrometry-based analysis and 16S rDNA gene sequencing were used to investigate the liver metabolome and gut microbiota. We found that while both and VSL#3 reduced hepatic fat content, outperformed VSL#3. Furthermore, probiotic treatment restored the β diversity of the gut flora and decreased the abundance of pathogenic bacteria such as . These probiotics altered the metabolism in MCD mice, especially the glycerophospholipid metabolism. In conclusion, our findings distinguished the role of and VSL#3 in NAFLD and indicated that oral-gavage probiotics remodel gut microbiota and improve metabolism, raising the possibility of using probiotics in the cure of NAFLD.
Curr Pharm Biotechnol. 2024
World J Hepatol. 2025-6-27
Metabolites. 2024-6-28
Front Cell Infect Microbiol. 2022
Intern Emerg Med. 2023-1
Acc Chem Res. 2022-11-1
Nat Rev Gastroenterol Hepatol. 2022-10